Global Conference on Biomarker Discovery and Molecular Analytics

The field of biomarker discovery and molecular analytics stands as a cornerstone in the development of personalized medicine, revolutionizing diagnostics, therapeutics, and patient management worldwide. Global advancements—propelled by breakthroughs in genomics, proteomics, artificial intelligence (AI), and high-throughput technologies—are uncovering novel biomarkers with unprecedented specificity and sensitivity.
Singapore, leveraging its robust biomedical infrastructure and strategic investments under the Research, Innovation and Enterprise (RIE) 2025 plan, has positioned itself at the forefront of advanced research. Initiatives like the Ignition AI Accelerator and partnerships between the Experimental Drug Development Centre (EDDC) and leading AI-driven companies exemplify Singapore’s commitment to integrating artificial intelligence, automation, and scientific expertise to streamline drug and biomarker discovery

By convening global experts, industry leaders, and regional stakeholders, Global Biomarkers 2026 conference aims to catalyze cross-border partnerships, showcase cutting-edge research, and drive actionable solutions to advance biomarker discovery and molecular analytics both globally and within the ASEAN context.

Biomarker Discovery and Molecular Analytics: Research Pain Points and Progress<

Pain Points
•    Biological Complexity and Heterogeneity complicates biomarker identification and clinical validation
•    Variability in data sources and difficulties in integrating multi-omics and clinical datasets
•    Underrepresentation of ethnicities in large-scale biomarker studies
•    Regulatory pathways for biomarker approval and integration into clinical practice
•    Cost, infrastructure, and accessibility challenges in Technology Adoption

Progress
•    Advancements in High-Throughput, genomics, proteomics, metabolomics, and AI-enhanced bioinformatics
•    Minimally invasive, real-time monitoring of disease progression and treatment
•    Singapore Nanopore Expression (SG-NEx) long-read RNA sequencing dataset
•    Biomarkers and Cognition Study, Singapore (BIOCIS) and the Ageing BIOmarker Study in Singaporeans (ABIOS)